AHSG

Across TCGA pan-cancer cohorts, AHSG mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AHSG data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AHSG mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AHSG expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where AHSG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.794	0.300	.002	18	view →
LUAD	DFS	Median	III,IV	0.485	0.995	.003	14	view →
HNSC	DFS	Median	All	0.860	0.361	.022	10	view →
OV	DFS	Quartile	All	0.547	0.884	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AHSG–CCRCC (DFS)

Open the CCRCC breakdown →